DRUG NEWS: Vioxx withdrawn from the market

November 2004 
Volume 34  Number 11
Pages 30 - 30
  PDF Version Available!

© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(11)             November 2004             p 30 Vioxx withdrawn from the market [DRUG NEWS: CARDIOVASCULAR RISKS]


In September, Merck & Co. voluntarily withdrew Vioxx (rofecoxib) from the worldwide market based on data from a large 3-year prospective clinical trial (Adenomatous Polyp Prevention on Vioxx, or APPROVe). Categorized as a selective nonsteroidal anti-inflammatory drug, Vioxx was FDA-approved to relieve pain from osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea.

The APPROVe trial, designed to test the effectiveness of Vioxx in preventing colorectal polyps in patients with a history of colorectal cancer, revealed an increased relative risk of cardiovascular events such as myocardial infarction and stroke beginning after 18 months of treatment. The risk of cardiovascular events wasn't increased during ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events